May 04, 2022
California is moving forward with a plan to manufacture and distribute more affordable versions of insulin under its Cal Rx generic label. The Department of Health Care Access and Information is requesting a one-time $100 million General Fund for the CalRx Biosimilar Insulin initiative. Through a contract partnership, the State would invest $50 million toward developing low-cost interchangeable biosimilar insulin products and an additional $50 million toward a California-based insulin manufacturing facility.
